AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2019
Mar 5, 2019
31523_dirs_2019-03-05_dd4b47bf-a68a-48de-8476-10ceddc1b477.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-03-01
Reporting Person: Crowley John F (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-03-01 | Common Stock | M | 10763 | $3.19 | Acquired | 678844 | Direct |
| 2019-03-01 | Common Stock | M | 8770 | $3.82 | Acquired | 687614 | Direct |
| 2019-03-01 | Common Stock | M | 467 | $6.45 | Acquired | 688081 | Direct |
| 2019-03-01 | Common Stock | S | 4618 | $12.9706 | Disposed | 683463 | Direct |
| 2019-03-01 | Common Stock | S | 15382 | $13.7876 | Disposed | 668081 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-03-01 | Stock Options (right to buy) | $3.19 | M | 10763 | Disposed | 2024-01-03 | Common Stock (10763) | Direct |
| 2019-03-01 | Stock Options (right to buy) | $3.82 | M | 8770 | Disposed | 2024-06-26 | Common Stock (8770) | Direct |
| 2019-03-01 | Stock Options (right to buy) | $6.45 | M | 467 | Disposed | 2022-02-15 | Common Stock (467) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.34 to $13.31. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.38 to $13.99. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: All of the options were fully vested and exercisable as of March 1, 2019